As Majority Of U.S. Patients Tested For JCV, Tysabri Sales Rise, Elan Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Irish company is still dealing with the after-effects of splitting apart its business in 2011, including its search for a new CEO. Meanwhile, Elan’s lead revenue driver, Tysabri continues to grow.